Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
28 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Anavex Life Sciences Corp.’s names, not what it holds today.
Patents granted
28
28 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 5 in 2023
Applications published
41
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'15'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals18
Chemical engineering2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ANAVEX LIFE SCIENCES CORP. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CH)
20 publishedANAVEX LIFE SCIENCES CORP. its own name
named as the applicant on its applications, in US
21 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 12, 2025 | 12,383,526 | Optimized sigma-1 agonist method of responder selection and treatment | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Apr 29, 2025 | 12,285,403 | A2-73 as a therapeutic for insomnia, anxiety and agitation | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Apr 22, 2025 | 12,280,034 | Sigma-1 receptor agonist systolic blood pressure therapy | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Jan 28, 2025 | 12,208,079 | Enantiomers of A2-73, analogues, and sigma agonist activity | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Dec 31, 2024 | 12,180,174 | A2-73 crystalline polymorph compositions of matter and methods of use thereof | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Nov 12, 2024 | 12,138,240 | Treatment of cardiac dysfunction | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Feb 13, 2024 | 11,896,590 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Dec 12, 2023 | 11,839,600 | Neurodevelopmental disorder therapy | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Nov 14, 2023 | 11,813,242 | A2-73 as a therapeutic for insomnia, anxiety, and agitation | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Jul 4, 2023 | 11,690,821 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0325514 | OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Oct 16, 2025 | 2025/0319057 | A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATION | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Sep 11, 2025 | 2025/0281447 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Apr 17, 2025 | 2025/0120938 | ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITY | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Apr 10, 2025 | 2025/0115566 | A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Feb 27, 2025 | 2025/0064772 | TREATMENT OF CARDIAC DYSFUNCTION | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Dec 19, 2024 | 2024/0417798 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| May 16, 2024 | 2024/0156810 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Feb 29, 2024 | 2024/0066003 | NEURODEVELOPMENTAL DISORDER THERAPY | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. |
| Feb 8, 2024 | 2024/0041818 | A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATION | Pharmaceuticals | ANAVEX LIFE SCIENCES CORP. · patent 12,285,403 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 10.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.